4164 Stock Overview
Operates as a pharmaceutical retailer in the Kingdom of Saudi Arabia and the United Arab Emirates. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Nahdi Medical Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ر.س119.60 |
| 52 Week High | ر.س156.80 |
| 52 Week Low | ر.س115.60 |
| Beta | 0.19 |
| 1 Month Change | -0.99% |
| 3 Month Change | -9.94% |
| 1 Year Change | -10.61% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.27% |
Recent News & Updates
Returns On Capital Signal Tricky Times Ahead For Nahdi Medical (TADAWUL:4164)
Oct 18
Nahdi Medical Company's (TADAWUL:4164) Share Price Is Matching Sentiment Around Its Earnings
Sep 13Recent updates
Returns On Capital Signal Tricky Times Ahead For Nahdi Medical (TADAWUL:4164)
Oct 18Nahdi Medical Company's (TADAWUL:4164) Share Price Is Matching Sentiment Around Its Earnings
Sep 13Nahdi Medical Company Beat Revenue Forecasts By 6.2%: Here's What Analysts Are Forecasting Next
Aug 07Nahdi Medical (TADAWUL:4164) Has Announced A Dividend Of SAR2.50
Aug 03Capital Allocation Trends At Nahdi Medical (TADAWUL:4164) Aren't Ideal
Jun 18There's No Escaping Nahdi Medical Company's (TADAWUL:4164) Muted Earnings
Apr 25Nahdi Medical (TADAWUL:4164) Is Paying Out A Dividend Of SAR3.00
Mar 21The Returns On Capital At Nahdi Medical (TADAWUL:4164) Don't Inspire Confidence
Jan 07Analyst Estimates: Here's What Brokers Think Of Nahdi Medical Company (TADAWUL:4164) After Its First-Quarter Report
Aug 07Here's What's Concerning About Nahdi Medical's (TADAWUL:4164) Returns On Capital
Jul 25Here's What's Concerning About Nahdi Medical's (TADAWUL:4164) Returns On Capital
Mar 22Nahdi Medical Company's (TADAWUL:4164) Price Is Out Of Tune With Earnings
Dec 13We Think Nahdi Medical's (TADAWUL:4164) Profit Is Only A Baseline For What They Can Achieve
Aug 20Are Investors Undervaluing Nahdi Medical Company (TADAWUL:4164) By 27%?
Aug 01Shareholder Returns
| 4164 | SA Consumer Retailing | SA Market | |
|---|---|---|---|
| 7D | -1.0% | -0.5% | -1.1% |
| 1Y | -10.6% | -5.6% | -9.0% |
Return vs Industry: 4164 underperformed the SA Consumer Retailing industry which returned -5.6% over the past year.
Return vs Market: 4164 underperformed the SA Market which returned -9% over the past year.
Price Volatility
| 4164 volatility | |
|---|---|
| 4164 Average Weekly Movement | 2.2% |
| Consumer Retailing Industry Average Movement | 3.5% |
| Market Average Movement | 4.0% |
| 10% most volatile stocks in SA Market | 7.7% |
| 10% least volatile stocks in SA Market | 2.5% |
Stable Share Price: 4164 has not had significant price volatility in the past 3 months compared to the SA market.
Volatility Over Time: 4164's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | n/a | Yasser Ghulam Abdulaziz Joharji | www.nahdi.sa |
Nahdi Medical Company operates as a pharmaceutical retailer in the Kingdom of Saudi Arabia and the United Arab Emirates. The company offers pharmaceutical and health products, such as health and wellness, mom and baby, beauty, and everyday essential products through retail and online stores. It also provides healthcare services, including polyclinics, express clinics, telemedicine services, and home healthcare, as well as operates an E-Pharmacist platform.
Nahdi Medical Company Fundamentals Summary
| 4164 fundamental statistics | |
|---|---|
| Market cap | ر.س15.70b |
| Earnings (TTM) | ر.س833.39m |
| Revenue (TTM) | ر.س9.30b |
18.7x
P/E Ratio1.7x
P/S RatioIs 4164 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4164 income statement (TTM) | |
|---|---|
| Revenue | ر.س9.30b |
| Cost of Revenue | ر.س5.88b |
| Gross Profit | ر.س3.42b |
| Other Expenses | ر.س2.58b |
| Earnings | ر.س833.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.41 |
| Gross Margin | 36.76% |
| Net Profit Margin | 8.96% |
| Debt/Equity Ratio | 0% |
How did 4164 perform over the long term?
See historical performance and comparisonDividends
4.6%
Current Dividend Yield86%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 15:13 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nahdi Medical Company is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Duaa AlFadda | BofA Global Research |
| Michel Salameh | Citigroup Inc |
| Ahmed Moataz | EFG-Hermes Research |